Expanded access program for tumor-related low blood sugar
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This program provides access to an investigational drug called ersodetug for people whose low blood sugar is caused by a tumor and hasn't improved with standard care. It's designed for those who can't join a regular clinical trial for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Low blood sugar caused by a tumor that hasn't improved with standard treatments.
- Unable to join any other clinical trial that is testing this drug.
- If you could become pregnant, you must not be pregnant or breastfeeding and must use birth control during treatment and for 5 months after the last dose.
- If you could make someone pregnant, you must either use birth control or abstain from sex during treatment and for 5 months after the last dose.
- No active HIV, hepatitis B, or hepatitis C infection.
- No known allergy to the study drug (ersodetug) or its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ersodetug in people whose neuroendocrine tumors cause dangerously low blood sugar that standard treatments can't control. If you need IV sugar or nutrition for at least a week, this trial may offer a new option to help manage your blood sugar.
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses immune cells from your own tumor, grown in the lab and given back to you, potentially to help your body fight the cancer.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Hear when a new Tumor-associated Hyperinsulinism (Tumor HI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.